Sodium-glucose cotransporter 2 inhibitors in patients with systemic lupus erythematosus and lupus nephritis: A systematic review and meta-analysis
- 20 October 2026
- journal article
- review article
- Published by SAGE Publications in Lupus
Abstract
Introduction: Systemic Lupus Erythematosus (SLE) and lupus nephritis (LN) carry substantial cardiorenal risks. Conventional immunosuppressive therapies primarily target inflammation but leave a burden of residual renal and metabolic damage. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) provide clear cardiorenal protection in general populations, but data specific to SLE remains limited. This systematic review and meta-analysis evaluated the efficacy and safety of SGLT2i in patients with SLE and LN. Methods: Comprehensive searches across five electronic databases (PubMed, Cochrane CENTRAL, Web of Science, Embase, and Scopus) were conducted up to April 2026 to identify randomized controlled trials (RCTs) and observational studies assessing SGLT2i in adult SLE/LN patients. Random-effects meta-analyses were performed to synthesize cardiorenal and safety outcomes using R Software. Results: Six studies published between 2024 and 2025 were included. Pooled data demonstrated that SGLT2i use was associated with a significant improvement in estimated glomerular filtration rate (eGFR) compared to controls (MD: 4.02; 95% CI: 1.39–6.65; I 2 = 60.1%). SGLT2i significantly reduced the risks of progression to end-stage kidney disease (RR: 0.37; 95% CI: 0.25–0.56; I 2 = 11.0%), heart failure development (RR: 0.65; 95% CI: 0.56–0.75; I 2 = 0.0%), incident lupus nephritis (RR: 0.58; 95% CI: 0.44–0.76; I 2 = 0.0%), and re-hospitalizations (RR: 0.67; 95% CI: 0.57–0.79; I 2 = 0.0%). Furthermore, a significant reduction in all-cause mortality was observed (RR: 0.55; 95% CI: 0.36–0.86; I 2 = 76.2%). SGLT2i treatment demonstrated an acceptable safety profile across the included cohorts. The certainty of evidence for these findings was rated as low to very low, and results remain vulnerable to residual confounding from variables such as disease activity, corticosteroid burden, and immunosuppressive regimen. Conclusion: Preliminary exploratory evidence suggests potential associations between SGLT2 inhibitors and cardiorenal outcomes in lupus nephritis. Given the low certainty of evidence and vulnerability to residual confounding from disease-specific variables, these hypothesis-generating findings require confirmation in well-designed randomized controlled trials.Keywords
This publication has 20 references indexed in Scilit:
- Can fibrate therapy redefine the management of diabetic retinopathy? A comprehensive systematic review and meta-analysis of efficacy and safetyJournal of Diabetes and its Complications, 2025
- Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidenceAsia-Pacific Journal of Ophthalmology, 2025
- Is there a link between dry eye disease and diabetes mellitus? A systematic review and meta-analysisJournal of Diabetes and its Complications, 2025
- Which treatment modality offers the best outcomes for diabetic retinopathy? A systematic review and network meta-analysisDiabetes Research and Clinical Practice, 2025
- Impact of SGLT2i on bone health in patients with lupus nephritis: randomized double blinded placebo-controlled clinical trialJournal Of Nephrology, 2025
- Kidney outcomes of systemic lupus erythematosus patients treated with SGLT2 inhibitors: A national cohort studySeminars in Arthritis and Rheumatism, 2025
- Efficacy and Safety of Sodium–Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Cardiovascular, Renal Events, and Safety Outcomes in Patients With Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes: A Population‐Based Target Trial EmulationArthritis & Rheumatology, 2024
- Sodium-Glucose Cotransporter-2 Inhibitors and Nephritis Among Patients With Systemic Lupus ErythematosusJAMA Network Open, 2024
- Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy2023
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2019